Nasdaq
$68.78▼ 0.49%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $224.8MShares out 3.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.6Pre-market26.10.06 20:246-KKey event#●●●
Sol-Gel Technologies Ltd.
Sol-Gel Technologies will hold its Annual Meeting of Shareholders on November 17, 2026, to vote on the appointment of auditors, re-election of directors, appointment of Moshe Arkin as CEO, a name change, and an increase in registered share capital. Shareholders of record as of October 7, 2026, are eligible to vote, and the Board of Directors recommends voting in favor of all proposals.…more
$68.78-0.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30Pre-market26.09.30 22:006-KKey event
Sol-Gel Technologies Ltd.
Sol-Gel Technologies will host a KOL Investor Day on October 14, 2026, in New York to discuss its lead investigational candidate, SGT-610 (patidegib gel, 2%). The event will feature medical experts who will address the significant disease burden of Gorlin Syndrome and the potential impact of the company's treatment.…more
$68.78-0.49%vs prev closeView filingShare - 9.17Pre-market26.09.17 21:306-KKey event
Sol-Gel Technologies Ltd.
Sol-Gel Technologies has completed the last patient last visit (LPLV) in its pivotal Phase 3 clinical trial for SGT-610, a treatment for Gorlin syndrome. The company is currently proceeding with database lock and statistical analysis, with top-line results expected to be reported in late November 2026.…more
$68.78-0.49%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30Pre-market26.09.30 22:14#●●●#●●●
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14…more
Sol-Gel Technologies will host a Key Opinion Leader investor event on October 14 to discuss its SGT-610 candidate for Gorlin Syndrome. The event aims to highlight the disease burden and unmet medical needs ahead of upcoming clinical results.…more
$68.78-0.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.17Pre-market26.09.17 21:30
●●●●●●●● ●●●●● ●●●●●●
Sol-Gel Technologies has completed the final patient visit for its Phase 3 clinical trial of SGT-610 for Gorlin syndrome. The company expects to report top-line results in late November 2026, though the outcome remains uncertain.…more
$68.78-0.49%vs prev close - 8.20Pre-market26.08.20 21:42
●●●●●●●● ●●●●● ●●●●●●
Sol-Gel Technologies reported a Q2 loss per share of $1.13, beating analyst estimates, with revenue of $591,000 also exceeding expectations. However, both earnings and revenue saw a significant decline compared to the same period last year, warranting caution regarding overall profitability.…more
$68.78-0.49%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report